210 results
6-K
EX-99.2
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.
About Rilzabrutinib
Rilzabrutinib is an oral
F-3ASR
EX-1.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and such Underwriters … investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to either
F-3ASR
EX-4.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based;
(3) a statement … that, in the opinion of each such individual, he has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether
6-K
EX-99.1
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
aims to restore balance between pro-inflammatory and regulatory T cells.
Amlitelimab is currently under clinical investigation, and its safety
6-K
EX-99.4
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.
Dupixent inhibits the signaling … inflammation in COPD.
Itepekimab is currently under clinical investigation, with two Phase 3 trials currently enrolling, and its safety and efficacy have
6-K
EX-99.2
ial4rdg
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.5
dx0id
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
h51em1 jypoas
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
q9ntruud
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.3
1wxd0 zd10
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.2
siv1rga n1
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
bjjc2
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.2
6mqcal tfk4nd
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.1
g2r2brnk0600
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.1
dan0yj
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.3
b1ce7u2uwp dj3c1dx
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
plnlw
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.2
25b 6k1uu90s08mv4
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
5zhtt4gwgs2y
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.3
zd6r3
5 Jul 23
Current report (foreign)
8:43am